Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Custodio AB et al. - Patients with early stage NSCLC are at substantial risk for recurrence even after potentially curative surgical resection, and adjuvant chemotherapy. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in an individual patient. Molecular markers may provide additional information about the likelihood of relapse beyond that obtained from pathologic staging. They may also have value in determining which patients will benefit from adjuvant platinum-based chemotherapy. This review focuses on:

  • Additional studies will be required to determine whether these markers are useful in selecting pts for adjuvant platinum based chemotherapy